Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure

Andrea CALCAGNO; NICOLE PAGANI; ALESSANDRA ARIAUDO; G Arduino; CHIARA CARCIERI; ANTONIO D'AVOLIO; Letizia MARINARO; M. C Tettoni; Laura TRENTINI; Giovanni DI PERRI; Stefano BONORA

doi:10.1093/jac/dkx052

Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure

Andrea CALCAGNO
, NICOLE PAGANI
, ALESSANDRA ARIAUDO
, G Arduino
, CHIARA CARCIERI
, ANTONIO D'AVOLIO
, Letizia MARINARO
, M. C Tettoni
, Laura TRENTINI
, Giovanni DI PERRI
, Stefano BONORA

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.

Original language	English
Pages (from-to)	1741-1744
Number of pages	4
Journal	Journal of Antimicrobial Chemotherapy
Volume	72
Issue number	6
DOIs	https://doi.org/10.1093/jac/dkx052
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/jac/dkx052

https://hdl.handle.net/11579/217069

Cite this

CALCAGNO, A., PAGANI, NICOLE., ARIAUDO, ALESSANDRA., Arduino, G., CARCIERI, CHIARA., D'AVOLIO, ANTONIO., MARINARO, L., Tettoni, M. C., TRENTINI, L., DI PERRI, G., & BONORA, S. (2017). Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. Journal of Antimicrobial Chemotherapy, 72(6), 1741-1744. https://doi.org/10.1093/jac/dkx052

@article{6fe3dadd593e4592a44ec0883e6f4d17,

title = "Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure",

abstract = "Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.",

author = "Andrea CALCAGNO and NICOLE PAGANI and ALESSANDRA ARIAUDO and G Arduino and CHIARA CARCIERI and ANTONIO D'AVOLIO and Letizia MARINARO and Tettoni, \{M. C\} and Laura TRENTINI and \{DI PERRI\}, Giovanni and Stefano BONORA",

year = "2017",

doi = "10.1093/jac/dkx052",

language = "English",

volume = "72",

pages = "1741--1744",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

CALCAGNO, A, PAGANI, NICOLE, ARIAUDO, ALESSANDRA, Arduino, G, CARCIERI, CHIARA, D'AVOLIO, ANTONIO, MARINARO, L, Tettoni, MC, TRENTINI, L, DI PERRI, G & BONORA, S 2017, 'Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure', Journal of Antimicrobial Chemotherapy, vol. 72, no. 6, pp. 1741-1744. https://doi.org/10.1093/jac/dkx052

TY - JOUR

T1 - Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure

AU - CALCAGNO, Andrea

AU - PAGANI, NICOLE

AU - ARIAUDO, ALESSANDRA

AU - Arduino, G

AU - CARCIERI, CHIARA

AU - D'AVOLIO, ANTONIO

AU - MARINARO, Letizia

AU - Tettoni, M. C

AU - TRENTINI, Laura

AU - DI PERRI, Giovanni

AU - BONORA, Stefano

PY - 2017

Y1 - 2017

N2 - Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.

AB - Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.

UR - https://iris.uniupo.it/handle/11579/217069

U2 - 10.1093/jac/dkx052

DO - 10.1093/jac/dkx052

M3 - Article

SN - 0305-7453

VL - 72

SP - 1741

EP - 1744

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -

Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this